Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis

Rheumatology

Volumn 46, Issue 5, 2007, Pages 783-789

  Terzioglu, E ^a   Bisgin, A ^a   Sanlioglu, A D ^a   Ulker, M ^a   Yazisiz, V ^a   Tuzuner, S ^a   Sanlioglu, S ^a  

^a AKDENIZ UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Adenovirus; Rheumatoid arthritis; SiRNA; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; DEATH RECEPTOR; DEATH RECEPTOR 1; DEATH RECEPTOR 2; DEATH RECEPTOR 3; DEATH RECEPTOR 4; DEATH RECEPTOR 4 DECOY RECEPTOR; GREEN FLUORESCENT PROTEIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL DEATH; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; FLOW CYTOMETRY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; DOWN REGULATION; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; METHODOLOGY; PATHOLOGY; SYNOVIUM;

ARTHRITIS, RHEUMATOID; CELL DEATH; CELLS, CULTURED; DOWN-REGULATION; GENE THERAPY; GENETIC VECTORS; HUMANS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SYNOVIAL MEMBRANE; TRANSDUCTION, GENETIC;

EID: 34347237670     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel448     Document Type: Article

References (42)

1. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
2. Takayanagi H, Juji T, Miyazaki T et al. Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J Clin Invest 1999;104:137-46.
3. Vaishnaw AK, McNally JD, Elkon KB. Apoptosis in the rheumatic diseases. Arthritis Rheum 1997;40:1917-27.
4. Chemajovsky Y, Annenkov A, Herman C et al. Gene therapy for rheumatoid arthritis. Theoretical considerations. Drugs Aging 1998;12:29-41.
5. Jorgensen C, Gay S. Gene therapy in osteoarticular diseases: Where are we? Immunol Today 1998;19:387-91.
6. Tomita T, Takeuchi E, Tomita N et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 1999;42:2532-42.
7. Chemajovsky Y, Gould D, Annenkov A et al. Immunotherapy of auto-immune diseases by gene transfer. Biochem Soc Trans 1999;27:869-73.
8. Wiley SR, Schooley K, Smolak PJ et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
9. Abe K, Kurakin A, Mohseni-Maybodi M, Kay B, Khosravi-Far R. The complexity of TNF-related apoptosis-inducing ligand. Ann N Y Aced Sci 2000;926:52-63.
10. Sheikh MS, Fornace AJJr.. Death and decoy receptors and p53-madiated apoptosis. Leukemia 2000;14:1509-13.
11. Sanlioglu AD, Koksal IT, Ciftcioglu A, Baykara M, Luleci G, Sanlioglu S. Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. J Urol 2007;177:359-64.
12. Meng RD, McDonald ER, 3rd, Sheikh MS, Fornace AJ Jr, El-Deiry WS. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL, p53-, and KILLER/ DR5-dependent colon cancer apoptosis. Mol Ther 2000;1:130-44.
13. Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA, Peschon J, Chen YH. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/-mice. Nat Immunol 2003;4:255-60.
14. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8.
15. Sheridan JP, Marsters SA, Pitti RM et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21.
16. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813-20.
17. Schneider P, Thome M, Burns K et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997;7:831-6.
18. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997;7:821-30.
19. Irmler M, Thorne M, Hahne M, Schneider P et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-5.
20. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998;161:2833-40.
21. Mageed RA, Adams G, Woodrow D, Podhajcer OL, Chemajovsky Y. Prevention of collagen-induced arthritis by gene delivery of soluble p75 tumour necrosis factor receptor, Gene Ther 1998;5:1584-92.
22. Oligino, T, Ghivizzani S, Wolfe D et al. Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis. Gene Ther 1999;6:1713-20.
23. Nita I, Ghivizzani SC, Galea-Lauri J et al. Direct gene delivery to synovium. An evaluation of potential vectors in vitro and in vivo. Arthritis Rheum 1996;39:820-8.
24. Amett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
25. Perlman H, Bradley K, Liu H et al. IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts, J Immunol 2003;170:838-45.
26. Perlman H, Georganas C, Pagliari LJ, Koch AE, Haines K 3rd, Pope RM. Bcl-2 expression in synovial fibroblasts is essential for maintaining mitochondrial homeostasis and cell viability. J Immunol 2000;164:5227-35.
27. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000;165:2886-94.
28. Sanlioglu AD, Aydin C, Bozcuk H, Terzioglu E, Sanlioglu S. Fundamental principals of tumour necrosis factor-alpha gene therapy approach and implications for patients with lung carcinoma. Lung Cancer 2004;44:199-211.
29. Sanlioglu S, Engelhardt JF. Cellular redox state alters recombinant adeno-associated virus transduction through tyrosine phosphatase pathways. Gene Ther 1999;6:1427-37.
30. Engelhardt JF, Yang Y, Stratford-Perricaudet LD et al. Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nat Genet 1993;4:27-34.
31. Karacay B, Sanlioglu S, Griffith TS, Sandler A, Bonthius DJ. Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. Cancer Gene Ther 2004;11:681-90.
32. Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G, Sanlioglu S. Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Cancer Gene Ther 2006;13:21-31.
33. Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 2005;5:54.
34. Perlman H, Nguyen N, Liu H et al. Rheumatoid arthritis synovial fluid macrophages express decreased tumor necrosis factor-related apoptosis-inducing ligand R2 and increased decoy receptor tumor necrosis factor-related apoptosis-inducing ligand R3. Arthritis Rheum 2003;48:3096-101.
35. Ichikawa K, Liu W, Fleck M et al. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 2003;171:1061-9.
36. Miyashita T, Kawakami A, Tamai M et al. Akt is an endogenous inhibitor toward tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in rheumatoid synoviall cells. Biochem Biophys Res Commun 2003;312:397-404.
37. Yao Q, Wang S, Gambotto A et al. Intra-articular adenoviral-mediated gene transfer of trail induces apoptosis of arthritic rabbit synovium. Gene Ther 2003;10:1055-60.
38. Yao Q, Seol DW, Mi Z, Robbins PD. Intra-articular injection of recombinant TRAIL induces synovial apoptosis and reduces inflammation in a rabbit knee model of arthritis. Arthritis Res Ther 2005;8:R16.
39. Morel J, Audo R, Hahne M, Combe B. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2005;280:15709-18.
40. Jungel A, Baresova V, Ospelt C et al. Trichostatin-A sensitizes rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis. Ann Rheum Dis 2006,65:910-12.
41. Miranda-Carus ME, Balsa A, Benito-Miguel M, De Ayala CP, Martin-Mola E. Rheumatoid arthritis synovial fluid fibroblasts express TRAIL-R2 (DR5) that is functionally active. Arthritis Rheum 2004;50:2786-93.
42. Sanlioglu AD, Koksal T, Baykara M, Luleci G, Karacay B, Sanlioglu S. Current progress in adenovirus mediated gene therapy for patients with prostate carcinoma. Gene Ther Mol Biol 2003;7:113-33.